Vivoryon Therapeutics NV (VVY) — Cash Flow-to-Debt Ratio
Vivoryon Therapeutics NV (VVY) has a Cash Flow-to-Debt Ratio of -1.42x as of December 2025, meaning its operating cash flow of €-3.96 Million could theoretically repay -1% of its total liabilities (€2.79 Million) in one year. See VVY working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Vivoryon Therapeutics NV Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Vivoryon Therapeutics NV across 15 annual periods. Also explore VVY net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Vivoryon Therapeutics NV (2011–2025)
Year-by-year debt coverage analysis for Vivoryon Therapeutics NV. For market capitalisation and broader financial context, see Vivoryon Therapeutics NV market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.03x | €-8.46 Million | €2.79 Million | ▲ +46.2% |
| 2024 | -5.63x | €-19.17 Million | €3.40 Million | ▼ -18.9% |
| 2023 | -4.74x | €-21.54 Million | €4.55 Million | ▼ -5.9% |
| 2022 | -4.47x | €-21.79 Million | €4.87 Million | ▼ -216.4% |
| 2021 | -1.41x | €-11.26 Million | €7.96 Million | ▲ +64.4% |
| 2020 | -3.97x | €-14.01 Million | €3.53 Million | ▼ -9.3% |
| 2019 | -3.63x | €-11.61 Million | €3.20 Million | ▼ -46.3% |
| 2018 | -2.48x | €-6.99K | €2.82K | ▲ +62.3% |
| 2017 | -6.59x | €-12.12K | €1.84K | ▼ -197.8% |
| 2016 | -2.21x | €-13.26K | €5.99K | ▼ -4.4% |
| 2015 | -2.12x | €-12.15K | €5.73K | ▼ -10.2% |
| 2014 | -1.92x | €-10.59K | €5.51K | ▼ -138.9% |
| 2013 | -0.80x | €-8.53 Million | €10.60 Million | ▲ +69.0% |
| 2012 | -2.59x | €-12.04 Million | €4.64 Million | ▲ +24.8% |
| 2011 | -3.45x | €-14.32 Million | €4.15 Million | — |